NASDAQ: ENTAEnanta Pharmaceuticals Inc Stock
$7.74+0.16 (+2.11%)
Updated Aug 14, 2025
ENTA Price
$7.74
Fair Value Price
N/A
Market Cap
$165.47M
52 Week Low
$4.09
52 Week High
$13.43
P/E
-1.79x
P/B
2.09x
P/S
2.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$64.81M
Earnings
-$92.01M
Gross Margin
100%
Operating Margin
-133%
Profit Margin
-142%
Debt to Equity
2.8
Operating Cash Flow
-$23M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENTA Overview
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENTA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENTA
Ranked#84 of 481
Ranked#84 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.94 | A | |
| $12.09 | A | |
| $37.89 | A |
Be the first to know about important ENTA news, forecast changes, insider trades & much more!
ENTA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ENTA is good value based on its book value relative to its share price (2.09x), compared to the US Biotechnology industry average (4.42x)
P/B vs Industry Valuation
ENTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ENTA due diligence checks available for Premium users.
Valuation
ENTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.79x
Industry
-116.18x
Market
36.29x
ENTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.09x
Industry
4.42x
ENTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENTA's financial health
Profit margin
Revenue
$18.3M
Net Income
-$18.3M
Profit Margin
-99.7%
ENTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ENTA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$301.0M
Liabilities
$221.8M
Debt to equity
2.8
ENTA's short-term assets ($222.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENTA's short-term assets ($222.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ENTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$17.5M
Investing
-$26.5M
Financing
-$6.4M
ENTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENTA vs Biotech Stocks
Enanta Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.